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INTRODUCTION
Alzheimer’s disease (AD) is the most common form 
of dementia with no test available that would accurately 
diagnose the disease during lifetime and no adequate 
treatments that would cure, delay its onset or retard pro-
gression of the disease. Currently, there are 18 million 
people with Alzheimer’s disease worldwide. With 
increasing life expectancy across the world, AD is a 
rapidly growing socioeconomic and medical problem. It 
is estimated that by the year 2040 there will be 81 mil-
lion people affected with AD (Ferri et al. 2005). It is 
believed that novel therapies for AD will benefit the 
most mildly cognitively impaired individuals (MCIs) or 
preclinical AD cases that do not show gross pathological 
changes in the brain (Morris 2005). In this respect, neu-
roimaging techniques as well as biomarkers have been 
investigated in order to identify such cases, to improve 
the accuracy of clinical diagnosis of Alzheimer’s disease 
and to monitor disease-modifying therapies. This is 
especially important in non-specialist settings where the 
clinical diagnostic accuracy is lower and where more 
expensive imaging techniques (PET) are not available. 
Until now, apolipoprotein E (APOE) ε4 allele remains 
the strongest genetic risk factor for Alzheimer’s disease 
(Corder et al. 1993, Saunders et al. 1993). 
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The key pathological features of Alzheimer’s 
disease are amyloid plaques (extracellular aggre-
gates of amyloid-β (Aβ) peptides) and neurofibril-
lary tangles (intracellular aggregates of hyperphos-
phorylated tau protein) in the brain. It appears that 
pathological processes that cause these aggregates 
begin 20−30 years before the onset of cognitive 
symptoms or significant neuronal loss (Morris 
2005). Decreased concentrations of amyloid-β42 
peptide (Aβ42) in the cerebrospinal fluid (CSF) 
have been consistently demonstrated in AD as well 
as in MCI cases together with increased concentra-
tions of total-tau (t-tau) and/or phosphorylated tau 
protein at position threonine181 (p181-tau) (Hulstaert 
et al. 1999, Riemenschneider et al. 2002, Hansson 
et al. 2006, Fagan et al. 2007, Mattsson et al. 2009). 
Most importantly, these biomarker changes were 
observed in non-demented individuals who will 
progress to AD (Fagan et al. 2007). The recently 
revised research criteria for AD have incorporated 
CSF biomarkers as supportive features in the diag-
nosis of AD (Dubois et al. 2007, Gauthier et al. 
2008). The latest survey across 23 European coun-
tries has shown that CSF biomarker testing is con-
sidered to be an important part of the dementia 
diagnostic work-up in most countries (Hort et al. 
2010). Since several drug candidates for Alzheimer’s 
disease are being evaluated in clinical trials, there 
will be a demand for accurate and early diagnosis 
of AD and for monitoring disease-modifying 
effects. 
In Croatia it is estimated that there are 40 000–
50 000 individuals with Alzheimer’s disease (www.
alzheimer.hr). The diagnosis of Alzheimer’s disease 
is made through a routine clinical work-up usually 
within the Departments of Neurology or Departments 
of Psychiatry. In Croatia there are no memory clin-
ics that would enable diagnosis of AD through a 
medical team specialized in dementia. In this study, 
we tested the benefit of analysis of the three proteins 
(Aβ42, t-tau and p181-tau) in the CSF of clinically 
diagnosed non-demented individuals, Alzheimer’s 
disease patients and patients with uncertain type of 
dementia in a setting with no specialized dementia 
centers, such as in Croatia. We show that in non-
specialized setting CSF biomarker testing may 
improve the diagnosis of AD and may detect early 
AD cases giving thus the chance for potential pre-
ventive therapy.
METHODS
Patients
Thirty-six patients of the Departments of Neurology 
at the University Hospitals in the two largest cities in 
Croatia, Zagreb and Split, were involved in this study. 
Fig. 1. CSF levels of Aβ42, t-tau and p181-tau as a function 
of clinical diagnosis. The levels of the three biomarkers were 
analyzed by ELISA assay (Innogenetics, Ghent, Belgium) 
among individuals clinically referred as non-demented 
(n=11), patients with AD (n=13) and individuals with uncer-
tain type of dementia (uncertain dementia, n=12). The 
median levels together with 25–75th percentile range are 
shown. Comparisons between groups were performed using 
nonparametric Mann-Whitney U test (*P<0.05; ** P<0.01). 
(Aβ42) amyloid-β42; (t-tau) total tau; (p181-tau) phospho-
rylated-tau; (AD) Alzheimer’s disease.
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The patients clinically referred as non-demented (n=11) 
were patients who were examined because of other neu-
rological problems that did not affect cognition such as 
headache, vertigo and back syndrome. Clinical diagno-
sis of probable Alzheimer’s disease (n=13) was made 
according to DSM-IV (Diagnostic and Statistical Manual 
of Mental Disorders, 4th edition) and the National 
Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) diagnostic 
criteria (McKhann et al. 1984). Dementia severity was 
assessed using the Mini-Mental State Examination 
(MMSE) (Folstein et al. 1975) and/or the Mattis Dementia 
Rating Scale (MDRS) (Miller and Pliskin 2006). Patients 
that were clinically diagnosed as uncertain dementia 
(n=12) presented individuals with dementia without cer-
tain diagnosis of the dementia type. Patients with other 
causes of cognitive impairment, including brain tumor, 
vitamin B12 deficiency, folate deficiency, thyroid dys-
function, depression, head trauma, CNS infection and 
current alcohol abuse were excluded. All patients or 
their closest relative (if patients were judged unable to 
give informed consent) gave written informed consent to 
participate and the study was approved by the local 
medical ethical committees.
CSF analysis
CSF (2 mL, n=36) was collected in polypropylene 
tubes. CSF samples were free from any blood contamina-
tions. Samples were gently inverted to avoid possible 
gradient effect and were aliquoted (0.5 mL) into polypro-
pylene tubes before freezing at −80°C. Measurements of 
CSF concentrations of amyloid-β42 (Aβ42), total-tau 
(t-tau) and phosphorylated tau at position threonine 181 
(p181-tau) were performed using commercially available 
ELISA assay (Innogenetics, Ghent, Belgium) according to 
the manufacturer’s protocol and blinded to clinical diag-
nosis of the studied subjects.
APOE genotyping
DNA was isolated from peripheral blood by a stan-
dard salting out procedure (Miller et al. 1988). APOE 
genotyping was performed using a PCR-RFLP method 
as described previously (Hixson and Vernier 1990). 
Subjects were classified according to their APOE 
genotype as APOE ε4-negative (ε2/ε3 and ε3/ε3) and 
APOE ε4-positive (ε3/ε4 and ε4/ε4) subjects. 
Statistical analysis
For statistical analysis software SPSS for Windows 
v 11.0 (Chicago, IL) was used. Comparisons between 
groups of subjects were performed using nonparamet-
ric Mann-Whitney U test. Results of the analyses were 
considered significant at P<0.05.
RESULTS
A summary of the demographic characteristics of 
the individuals tested is given in Table I. According to 
their clinical assessment individuals were grouped as 
non-demented, individuals with Alzheimer’s disease 
Table I
Demographic data of individuals tested
Non-demented Alzheimer’s disease Uncertain dementia
n 11 13 12
Age 63 ± 13.98* 76 ± 8.64 72.5 ± 11.29
Sex, F/M (%F) 8/3 (72.2) 6/7 (46.2) 7/5 (58.3)
MMSE score 28 ± 1.29 17 ± 4.72 19 ± 2.40
MDRS score NA 106.5 ± 19.27 106.5 ± 12.98
The data are presented as median ± SD. The patients were grouped according to their clinical diagnosis: Non-demented, 
Alzheimer’s disease, Uncertain dementia. (MMSE) Mini-Mental State Examination; (MDRS) Mattis Dementia Rating 
Scale; (NA) not available. * Note that non-demented group is younger that AD/uncertain dementia group.
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(AD) and individuals with uncertain type of dementia 
(uncertain dementia).
CSF biomarkers as a function of clinical 
diagnosis
The results of the levels of amyloid-β42 peptide (Aβ42), 
total-tau (t-tau) and phosphorylated tau at position 181 
(p181-tau) in 36 CSF samples of clinically assessed indi-
viduals are shown in Figure 1. In clinically assessed AD 
group the median Aβ42 was 533.4 pg/mL and was sig-
nificantly lower compared to the median level in non-de-
mented controls (802.1 pg/mL, P<0.05). In addition, 
among clinically assessed individuals with uncertain type 
of dementia (uncertain dementia) median Aβ42 level 
(543.1 pg/mL) was also significantly lower (P<0.05) than 
the level in non-demented control group. In clinically 
assessed AD group median t-tau (426.6 pg/mL) and p181-
tau levels (72.7 pg/mL, P<0.05) were higher than the 
median levels in the non-demented control group (191.2 
pg/mL for t-tau and 24.4 pg/mL for p181-tau), although 
only levels of p181-tau showed significant increase. 
Median levels of t-tau (364.6 pg/mL) and p181-tau (56.3 
pg/mL) in patients with uncertain type of dementia were 
also increased compared to the levels in non-demented 
controls, but this difference was not statistically signifi-
cant (Fig. 1). These results show that CSF samples of both 
clinically assessed AD and uncertain dementia individu-
als display altered median levels of Aβ42, t-tau and p181-
tau compared to the levels in the CSF of non-demented 
controls. In accord with previous studies (Hulstaert et al. 
1999, Riemenschneider et al. 2002, Hansson et al. 2006, 
Fagan et al. 2007, Mattsson et al. 2009) our clinically 
assessed AD individuals showed decreased median Aβ42 
levels and increased median t-tau or p181-tau levels in 
their CSF.
Utility of CSF biomarker cut-off values for 
improving accuracy of AD diagnosis and for 
identifying individuals with incipient AD
We applied externally established AD/MCI CSF 
cut-off values of low Aβ42 (≤530 pg/mL) and high 
t-tau (≥350 pg/mL) or high p181-tau (≥52 pg/mL) levels 
to our CSF samples (Hansson et al. 2006, Tapiola et al. 
2009), regardless of their clinical status, to identify 
individuals with AD/MCI CSF profile who are at high 
risk for probable AD. We set three groups taking into 
account positivity for 0, 1 or 2/3 CSF AD/MCI bio-
marker cut-off values. Normal CSF group (n=10) had 
all three biomarkers within normal range (Aβ42>530 
pg/mL, t-tau<350 pg/mL and p181-tau<52 pg/mL) (0/3 
positivity). AD/MCI CSF group (n=12) had a patho-
logical (or Alzheimer’s disease indicative) CSF pattern 
of decreased Aβ42 (≤530 pg/mL) and increased t-tau 
(≥350 pg/mL) or p181-tau (≥52 pg/mL) levels (2/3 
positivity). Other CSF group (n=14) showed a change 
in only one biomarker (1/3 positivity), i.e. had either 
Fig. 2. Comparison between clinical diagnosis and CSF profiling. Among clinically diagnosed groups, three CSF profiles 
were identified taking into account positivity for 0, 1 or 2/3 CSF AD/MCI biomarker cut-off values (Aβ42≤530 pg/mL, 
t-tau≥350 pg/mL or p181-tau≥52 pg/mL): normal CSF profile (0/3 positivity), other CSF profile (1/3 positivity) and AD/
MCI CSF profile (2/3 positivity). (AD) Alzheimer’s disease; (CSF) cerebrospinal fluid; (MCI) mild cognitive impairment; 
(Aβ42) amyloid-β42; (t-tau) total tau; (p181-tau) phosphorylated-tau. 
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decreased Aβ42 (≤530 pg/mL) or increased t-tau (≥350 
pg/mL) or p181-tau (≥52 pg/mL) levels. 
Applying these CSF cut-off values revealed that in 
each clinically assessed group there may be false posi-
tive and/or false negative cases (Fig. 2). In more detail, 
among 11 clinically assessed non-demented individu-
als the set CSF cut-offs identified 1 individual (9.1%) 
who showed a typical AD/MCI CSF pattern (2/3 posi-
tivity) and 3 individuals (27.3%) who showed a change 
in only one biomarker (1/3 positivity) (Fig. 2). MMSE/
MDRS scoring of these four individuals was repeated 
and indicated that they may have probable Alzheimer’s 
disease (mean MMSE 16.67, mean MDRS 103). Follow-
up clinical assessment of these individuals is under-
way. Among clinically diagnosed AD and uncertain 
dementia cases, the set cut-off values identified AD/
MCI-CSF pattern (2/3 positivity) in approximately 
45% of patients in both groups (Fig. 2). Surprisingly, 
CSF profiling revealed individuals with normal CSF 
pattern (0/3 positivity) in both clinically diagnosed AD 
and uncertain dementia cases.  
Next, in clinically assessed groups (non-demented, 
AD and uncertain dementia) we analyzed all three 
biomarkers in a two-dimensional format by plotting 
the p181-tau concentration (x-axis) versus the IATI 
index [Innotest Amyloid Tau Index, IATI = Aβ42/(240 
+ 1.18 t-tau), y-axis] (Fig. 3). The IATI<1 was reported 
for individuals with a typical AD biomarker profile, 
while IATI>1 was found to be characteristic for healthy 
control subjects (Riemenschneider et al. 2002). Indeed, 
all our subjects who had normal CSF profile (0/3 posi-
tivity, black) had IATI>1 and those with AD/MCI CSF 
pattern (2/3 positivity, light gray) had IATI<1 (Fig. 3), 
suggesting that the applied CSF profiling and/or IATI 
index can be useful for discriminating probable AD 
patients from non-demented individuals. Furthermore, 
majority of individuals  (9/14, 64.3%) showing only 1 
biomarker positivity of the AD/MCI CSF cut-off val-
ues (1/3 positivity, dark gray) showed IATI<1, indicat-
ing that in this group majority of patient may indeed 
have Alzheimer’s type dementia which needs to be 
clarified by further clinical follow-up. Furthermore, 
2/13 (15.4%) clinically diagnosed AD patients showed 
normal CSF profile (0/3 positivity, black) and IATI>1 
characteristic for healthy individuals. Additionally, 
3/11 (27.3%) clinically referred non-demented control 
subjects showed IATI<1 a typical AD biomarker pro-
file. Applying IATI index confirmed a possible false 
positive and false negative clinically diagnosed cases.
When p181-tau cut-off value (≥52 pg/mL) was 
applied to IATI index (Fig. 3), we identified that in 
AD/MCI CSF group 4/12 samples (33.3%) had p181-
tau<52 pg/mL, implying that, in contrast to IATI index 
(Aβ42 and t-tau values), p181-tau biomarker may not be 
Fig. 3. Scatter plot of IATI index and p181-tau levels among clinically referred non-demented individuals, AD patients and 
individuals with uncertain dementia in relation to CSF profiling. All three biomarkers were analyzed in a two-dimensional 
format by plotting the p181-tau levels (x-axis) versus the IATI index [IATI = Aβ42/(240 + 1.18 t-tau), y-axis]. Clinical diag-
nosis of non-demented individuals (square), AD (circle) and uncertain dementia (triangle) patients is shown as a function of 
IATI index and the levels of CSF p181-tau. Filled shapes represent the results of CSF profiling: normal CSF profile (0/3 
positivity, black), other CSF profile (1/3 positivity, dark gray) and AD/MCI CSF profile (2/3 positivity, light gray). (AD) 
Alzheimer’s disease; (CSF) cerebrospinal fluid; (MCI) mild cognitive impairment; (p181-tau) phosphorylated-tau; (IATI) 
Innotest Amyloid Tau Index.
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a perfect candidate to clearly discriminate AD/MCI 
from non-AD CSF pattern. 
Apolipoprotein E genotype in relation to CSF 
biomarker profiling 
Apolipoprotein E ε4 allele is the strongest genetic 
risk factor for Alzheimer’s disease detected so far 
(Corder et al. 1993, Saunders et al. 1993). Analysis of 
APOE genotype according to CSF biomarker profiling 
showed that all individuals having normal CSF profile 
(0/3 positivity, n=10) were APOE ε4-negative, while 
those with AD/MCI (2/3 positivity, n=12) and other 
(1/3 positivity, n=14) CSF profile were 71.4% and 30% 
APOE ε4-positive, respectively (Fig. 4). Although our 
sample size is too small to draw any strong conclusions 
our results are in agreement with previous genetic 
studies (Corder et al. 1993, Saunders et al. 1993) and 
support that APOE ε4 allele is associated with the CSF 
biomarker changes typical for Alzheimer’s disease 
(Riemenschneider et al. 2000).
DISCUSSION
If left underdiagnosed and untreated Alzheimer’s 
disease will become a major health problem. In Western 
high income countries in the past several years an urged 
need for early diagnosis of AD has opened new avenues 
of AD research developing neuroimaging techniques 
and/or searching for biomarkers that will detect early 
pathological changes characteristic for AD. Unlike most 
of the CSF biomarker studies that were conducted in 
settings within specialized AD research centers or 
memory clinics (Hulstaert et al. 1999, Riemenschneider 
et al. 2002, Hansson et al. 2006, Fagan et al. 2007, 
Mattsson et al. 2009), we evaluated the benefit of the 
analysis of the three biomarkers (Aβ42, t-tau and p181-
tau) in the CSF as a part of routine clinical work-up 
within Neurology clinics with no specialized dementia 
centers, such as in Croatia. In this study we showed that 
clinical diagnosis in Croatia is not very accurate (show-
ing both false positive and false negative cases). Thus, 
we consider the usage of clinical diagnosis as a gold 
standard and the tool for measuring biomarker sensitiv-
ity and specificity inappropriate in this study. Sensitivity 
and specificity of CSF biomarkers and IATI index for 
distinguishing Alzheimer’s disease from non-Alzheimer 
dementia and non-demented group were determined in 
more extensive studies by others  (Hansson et al. 2006, 
Tapiola et al. 2009, Mattsson et al. 2009). The scope of 
our study was not to confirm reliability of CSF biomark-
ers, rather to show how they can aid in differential diag-
nosis of AD in a setting with no dementia centers/
memory clinics. Indeed, we show that in such non-spe-
cialized settings clinical evaluation together with CSF 
biomarker testing when applied with a pathological (or 
AD/MCI-indicative) CSF cut-off values (Hansson et al. 
2006, Tapiola et al. 2009) may improve the accuracy of 
AD diagnosis among individuals with diagnostic doubts 
and may identify non-demented individuals with early 
CSF pathological changes characteristic for AD (incipi-
ent AD). Thus, in such settings CSF biomarkers may, be 
useful as a screening tools selecting individuals at high 
risk of developing Alzheimer’s disease who need to 
Fig. 4. APOE genotyping in relation to CSF profiling. Individuals were classified according to their APOE genotype as 
APOE ε4-negative (ε2/ε3 and ε3/ε3) and APOE ε4-positive (ε3/ε4 and ε4/ε4) subjects. (AD) Alzheimer’s disease; (CSF) 
cerebrospinal fluid; (MCI) mild cognitive impairment; (ApoE) apolipoprotein E.
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receive a detailed further clinical follow-up. Early 
changes in CSF biomarker profile before clinical symp-
toms appear have been reported in several studies that 
involved mildly cognitively impaired cases (MCIs) as 
well as non-demented individuals who will progress to 
AD (Riemenschneider et al. 2002, Hansson et al. 2006, 
Fagan et al. 2007, Mattsson et al. 2009). In accord with 
previous studies, we also showed that APOE ε4 allele, 
the strongest genetic risk factor for AD, is associated 
with AD/MCI CSF profile. Although AD/MCI CSF pat-
tern does not confirm the diagnosis of probable AD per 
se, it may help identifying and/or predicting individuals 
with incipient AD through their further clinical follow-
up (Hansson et al. 2006).  Due to a small sample size in 
this pilot study we acknowledge that our results need to 
be further validated on a larger sample size and con-
firmed with a follow-up clinical assessment of individu-
als who showed a characteristic AD/MCI CSF profile.
The newly revised research criteria for AD have 
incorporated CSF biomarker levels as supportive tests 
for the disease diagnosis, especially in cases of diagnos-
tic doubts and in cases of incipient AD (Dubois et al. 
2007, Gauthier et al. 2008, Sperling et al. 2011). 
Improving the inter-laboratory variability in CSF bio-
markers for AD (Mattsson et al. 2010) and standardizing 
the cut-off values of the three CSF biomarkers is greatly 
appreciated, especially in routine CSF testing for identi-
fying MCI individuals and even for predicting cognitive 
decline in non-demented adults. Since CSF tests are 
cheaper and more readily available than more expensive 
imaging techniques (PET, MRI), we conclude that they 
may become an important part of the dementia diagnos-
tic work-up, especially in countries with non-specialist 
settings. In the light of upcoming therapies aimed at 
slowing the progression and/or treating AD, it is of par-
ticular interest to identify MCI and non-demented sub-
jects with a highest risk for progression to AD.  
CONCLUSION
Early and accurate diagnosis of Alzheimer’s disease is 
crucial for applying novel therapies to treat, prevent or 
slower progression of this devastating disorder. In this 
study we show that in settings with no specialized AD 
centers or memory clinics CSF biomarker profiling and/or 
IATI index (IATI = Aβ42/(240 + 1.18 t-tau) may improve 
the accuracy of clinical diagnosis of AD among individu-
als with diagnostic doubt and also may help identifying 
individuals with incipient Alzheimer’s disease. 
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